Boomi to Simplify and Accelerate the Move to SAP Datasphere
Boomi™, the intelligent integration and automation leader, today announced an enhanced version of Boomi for SAP to help accelerate the migration of SAP Business Warehouse (SAP BW) customers to SAP Datasphere. By leveraging Amazon Web Services (AWS), Boomi aims to address the critical challenge of enterprise customers who need to transition to SAP Datasphere, and unlock the full potential of their business data in a cost-effective and streamlined way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509748233/en/
Boomi to Simplify and Accelerate the Move to SAP Datasphere (Graphic: Business Wire)
Addressing a Critical Challenge in Data Migration
With mainstream support ending for SAP BW coming at the close of 2027, SAP BW customers are encouraged to migrate to SAP Datasphere, which will enable business transformation by delivering seamless, scalable access to business-critical data. However, the move to SAP Datasphere requires significant investment and substantial effort from highly-skilled individuals.
Boomi for SAP accelerates the transition to SAP Datasphere on AWS through Boomi’s low-code, integration platform. Customers can simply log into the Boomi Enterprise Platform and leverage a pre-built accelerator specifically designed to speed the migration and integration of data into SAP Datasphere on AWS.
“SAP Datasphere is SAP's foundation for a business data fabric, but many companies with earlier versions of SAP BW are overburdened with the cost-prohibitive, time-consuming, and resource-intensive process of migrating to it,” said Steve Lucas, CEO at Boomi. “This new collaboration leverages Boomi’s expertise in intelligent integration and automation, along with AWS services, to provide a lighter, faster, more cost-effective way for organizations to transition to SAP Datasphere, getting the most out of their SAP investments and their data.”
Key benefits of Boomi for SAP include:
- Avoid costly SAP BW version upgrades and the need for a staging area, resulting in time and cost savings
- The ability to select which SAP BW Queries and BW InfoProviders to move to Datasphere
- Efficient data tiering to SAP Datasphere and Amazon Redshift, a fully managed, petabyte-scale data warehouse service, enabling businesses to move less frequently used data to more affordable cloud storage tiers
- Faster integration of third-party data into SAP Datasphere at a lower cost
- Better data preparation for more efficient use of data analytics and artificial intelligence (AI)
- A smooth procurement process in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS
“The ability to aggregate diverse datasets is emerging as a critical advantage as organizations recognize the pivotal role of AI in their operations,” said Matt Aslett, director of research at Ventana Research, part of ISG. “Data preparation and integration is imperative to ensuring more efficient utilization of data analytics and AI, and the acceleration of business outcomes through data-driven decision-making.”
“Working with AWS reinforces Boomi’s commitment to delivering a practical path to enterprise analytics and AI, beginning with a robust data foundation,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “With the Boomi Enterprise Platform, organizations can achieve a more flexible, scalable, and connected ecosystem to drive innovation, future-proof their IT investments, reduce total cost of ownership, and enhance business outcomes.”
Availability
Boomi for SAP is available in AWS Marketplace, and on the Boomi Enterprise Platform.
Additional Resources
- Find Boomi in AWS Marketplace
- Explore Boomi Recipes and Accelerators for SAP in the Discover Catalog
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509748233/en/
Contact information
Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom